title: Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
abstract: OBJECTIVE
  The objective of this paper is to assess if disease activity, systemic inflammation and metabolic syndrome are potential determinants of circulating adiponectin and resistin levels in ankylosing spondylitis (AS) patients undergoing TNF-α antagonist therapy.
  
  
  METHODS
  We investigated adiponectin and resistin serum concentrations in a series of 29 non-diabetic AS patients without history of cardiovascular (CV) events that were treated with the TNF-α antagonist infliximab, immediately prior to an infliximab infusion. Adipokine levels were also determined immediately after administration of an infliximab dose.
  
  
  RESULTS
  A significant correlation between adiponectin concentrations and insulin sensitivity (QUICKI at the time of the study) was seen (r=0.384; p=0.05). Also, a marginally significant negative correlation between adiponectin serum levels and the body mass index was observed (r=-0.367; p=0.07). Circulating adiponectin and resistin concentrations did not correlate with disease duration, erythrocyte sedimentation rate, C-reactive protein, BASDAI or VAS at the time of the study. However, AS patients with hip involvement or synovitis and/or enthesitis in other peripheral joints had higher adiponectin concentrations than those who did not have these complications (p-value for both comparisons =0.01). Adiponectin and resistin levels did not change upon infliximab administration.
  
  
  CONCLUSIONS
  The present study shows that in non-diabetic patients with AS on treatment with infliximab adiponectin and resistin serum levels do not correlate with disease activity. Nevertheless, adiponectin concentration correlates with insulin sensitivity. This finding raises the possibility that low circulating adiponectin concentrations may be involved in the pathogenesis of the CV disease in AS.
authors.affiliation: Rheumatology Division, Hospital Xeral-Calde, Lugo, Spain. jose.alberto.miranda.filloy@sergas.es
authors.forename: José A
authors.initials: JA
authors.lastname: Miranda-Filloy
authors.forename: Raquel
authors.initials: R
authors.lastname: López-Mejias
authors.forename: Fernanda
authors.initials: F
authors.lastname: Genre
authors.forename: Beatriz
authors.initials: B
authors.lastname: Carnero-López
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Ochoa
authors.forename: Teresa
authors.initials: T
authors.lastname: Diaz de Terán
authors.forename: Carlos
authors.initials: C
authors.lastname: González-Juanatey
authors.forename: Ricardo
authors.initials: R
authors.lastname: Blanco
authors.forename: Javier
authors.initials: J
authors.lastname: Llorca
authors.forename: Miguel A
authors.initials: MA
authors.lastname: González-Gay
mesh_terms: D054392:Adipokines / Q000097:blood; D052242:Adiponectin / Q000097:blood*; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000097:blood / Q000150:complications; D015331:Cohort Studies; D005260:Female; D006801:Humans; D000069285:Infliximab; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D052243:Resistin / Q000097:blood*; D013167:Spondylitis, Ankylosing / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D054392:Adipokines; D052242:Adiponectin; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D052243:Resistin; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D000069285:Infliximab